secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-09-29T20:05:25+00:00
Accession:  0001213900-26-104647
Event type: other
Sentiment:  neutral
Materiality: 0.28
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cadrenal holders approve equity plan boost to 1,000,000 shares and 960,000-share warrant issuance
--------------------------------------------------------------------------------

- Stockholders approved Amendment No. 2 to the 2022 Successor Equity Incentive Plan, raising the share reserve by 323,542 shares to 1,000,000 shares; the ISO limit was also raised to 1,000,000.
- Quang X. Pham was elected Class I director with 1,039,666 votes for and 14,342 withheld, to serve until the 2029 annual meeting.
- Holders approved issuance of up to 960,000 shares of common stock upon exercise of Series C-1 warrants issued in the private placement that closed July 1, 2026, per Nasdaq Rule 5635(d).
- WithumSmith+Brown, P.C. ratified as independent auditor for the fiscal year ending December 31, 2026 (2,110,693 for, 39,121 against, 5,527 abstentions).
- Record date July 27, 2026: 3,567,592 shares outstanding, with 2,155,341 shares represented (quorum) at the September 24, 2026 meeting; the adjournment proposal passed but was not needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026104647/0001213900-26-104647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026104647/ea0306613-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer